Meb Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 50.00 K
as on 16-11-2024
- Company Age 5 Year, 10 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.25 Cr
as on 16-11-2024
- Revenue -1.78%
(FY 2023)
- Profit 10.49%
(FY 2023)
- Ebitda 24.60%
(FY 2023)
- Net Worth -14.37%
(FY 2023)
- Total Assets 30.94%
(FY 2023)
About Meb Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 50.00 K .
The company currently has active open charges totaling ₹1.25 Cr.
Mangesh Bhad and Eknath Bhad serve as directors at the Company.
- CIN/LLPIN
U24304MH2020PTC335518
- Company No.
335518
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Akola, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Meb Pharma Private Limited offer?
Meb Pharma Private Limited offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs, Pharma Ingredients & Raw Materials, Pharmaceutical Excipients, API (Active Pharmaceutical Ingredients), Pharmaceutical Pellets, Food Acidulant, Fumaric Acid.
Who are the key members and board of directors at Meb Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mangesh Bhad  | Director | 06-Jan-2020 | Current |
| Eknath Bhad | Director | 06-Jan-2020 | Current |
Financial Performance of Meb Pharma.
Meb Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.78% decrease. The company also saw a substantial improvement in profitability, with a 10.49% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meb Pharma?
Unlock access to Meb Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jul 2023 | ₹1.25 Cr | Open |
How Many Employees Work at Meb Pharma?
Meb Pharma has a workforce of 64 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meb Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meb Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
